ARCHIVES

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

This article is from The Cancer Letter archive.

Vol. 07 No. 21 | May 22, 1981

Download PDF Visit The Full Archive

Related Articles

Oxaliplatin Regimens Extend Survival Of Advanced Colorectal Cancer, Study Finds

June 27, 2003

Also FDA clarifies data requirements for phase I IND applications.

April 29, 2005

NCI To Slow New Center Development To Assure Funding For Existing Commitments, King Says

February 14, 1975

AMC Cancer Center, Rose Cancer Program Name Douglass Tormey Director; ECG Plans Move To Denver

September 4, 1992

NCI Grant Awards

October 8, 1993

Greenwald Lists Plans For $40 Million Raise In Prevention & Control

December 3, 1993